# US 8,772,284 B2 · Method of treating cancer using combination of a bifunctional alkylating agent and DNA repair inhibitors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 8,772,284 B2
- Document ID: US8772284B2
- Status: Granted
- Kind: B2
- Application number: 13/504,943
- Filed: 2010-10-27
- Published: 2013-07-25
- Granted: 2014-07-08
- Earliest claimed: 2009-10-28
- Assignees: Academia Sinica
- Applicants: Te-Chang Lee; Tsann-Long Su; Ting-Chao Chou
- Inventors: Te-Chang Lee; Tsann-Long Su; Ting-Chao Chou
- Web page: https://patentgrep.com/patent/US8772284B2

## CPC

- A61K 33/36: Arsenic; Compounds thereof
- A61K 31/407: condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
- A61K 31/5377: not condensed and containing further heterocyclic rings, e.g. timolol
- A61K 31/7064: containing condensed or non-condensed pyrimidines
- A61K 31/7076: containing purines, e.g. adenosine, adenylic acid
- A61P 35/00: Antineoplastic agents
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A pharmaceutical composition for treating cancer, in particular drug resistant cancer, comprising an effective amount of bifunctional alkylating agent, an effective amount of a DNA repair inhibitor, and a pharmaceutically acceptable carrier.

## Claims

### Claim 1

A pharmaceutical composition for treating cancer comprising an effective amount of a derivative of 3a-aza-cyclopentaindene selected from the group consisting of BO-1012, an effective amount of a DNA repair inhibitor, and a pharmaceutically acceptable carrier.

### Claim 2 (depends on 1)

The composition of claim 1 wherein the DNA repair inhibitor is selected from the group consisting of arsenic trioxide, LY294002, and triciribine.

### Claim 3

A method of treating cancer suffered by a mammalian subject comprising administering to the subject an effective amount of BO-1012 and an effective amount of a DNA repair inhibitor.

### Claim 4 (depends on 3)

The method of claim 3 wherein the subject is administered with the BO-1012 before being administered with the DNA repair inhibitor.

### Claim 5 (depends on 3)

The method of claim 3 wherein the DNA repair inhibitor is selected from the group consisting of ATO, Ly294002, and triciribine.

### Claim 6 (depends on 3)

The method of claim 3 wherein the cancer is resistant to an individual therapeutic agent.

### Claim 7 (depends on 3)

The method of claim 3 wherein the cancer is human lung cancer.

### Claim 8 (depends on 3)

The method of claim 3 wherein the cancer is human bladder cancer.

### Claim 9 (depends on 3)

The method of claim 3 wherein the cancer is human breast cancer.

### Claim 10 (depends on 3)

The method of claim 3 wherein the cancer is human prostate cancer.

### Claim 11 (depends on 3)

The method of claim 3 wherein the cancer is human glioma cancer.

### Claim 12 (depends on 3)

The method of claim 3 wherein the cancer is human oral cancer.

### Claim 13

A pharmaceutical composition for treating cancer comprising an effective amount of BO-1509, an effective amount of a DNA repair inhibitor, and a pharmaceutically acceptable carrier.

### Claim 14 (depends on 13)

The composition of claim 13 wherein the DNA repair inhibitor is selected from the group consisting of arsenic trioxide, LY294002, and triciribine.